Typhoid remains a persistent contributor to childhood morbidity in communities lacking sanitation infrastructure. Typhoid conjugate vaccine (TCV) is effective in reducing disease risk in vaccinees; however, the duration of protection is unknown. This study measured the longevity of immune response to TCV in children aged under 10 years in Hyderabad, Pakistan, where an outbreak of extensively drug-resistant typhoid has been ongoing. A subset of children who received the TCV as part of the outbreak response were enrolled purposively from March 2018 to February 2019. The participants were followed up until January 2023. Blood samples were taken at baseline, 4-6 weeks, 6 months, and annually 1-4 years after vaccination to measure anti-Vi immunoglobulin (Ig) G levels using enzyme-linked immunosorbent assay. Active phone-based surveillance was performed to identify breakthrough infections. Blood culture was offered to any child with a history of fever ≥3 days within the last 7 days. A total of 81 children received a second dose of TCV in November 2019 during a catch-up campaign organized by the Sindh government. Nearly all participants seroconverted (802 of 837; 95.8%) at 4-6 weeks after vaccination. A total of 4 years after vaccination, 438 of 579 (75.6%) participants remained above the seroconversion threshold. The geometric mean titer (U/mL) of anti-Vi IgG at 4-6 weeks was 832.6 (95% confidence interval [CI]: 768.0-902.6); at 4 years after vaccination, the geometric mean titers in children aged 6 months to 2 years (12.6, [95% CI: 9.8-16.3]) and >2-5 years (40.1, [95% CI: 34.4-46.6]) were lower than in children aged >5-10 years (71.1, [95% CI: 59.5-85.0]). During 4 years of follow-up, nine children had culture-confirmed Salmonella Typhi infection; these infections occurred after a median duration of 3.4 years. All enteric fever cases seroconverted at 4-6 weeks after vaccination and seven (70.0%) remained seroconverted 4 years after vaccination. We observed 95.8% seroconversion after a single dose of TCV. There was a decay in anti-Vi IgG titers, and, at 4 years, approximately 75.6% remained seroconverted. There was a faster decay in children aged ≤2 years. Breakthrough infections were documented after a median 3.4 years after vaccination.
Enteric fever remains a public health concern in communities lacking sanitation infrastructure to separate sewage from drinking water. To bridge the gap until large-scale civil-engineering projects are implemented in high-burden countries, typhoid conjugate vaccine presents a promising disease-prevention technology. A new typhoid conjugate vaccine was prequalified by the World Health Organization in 2017 and is beginning to be introduced in countries around the world. To help inform vaccine introduction, the Surveillance for Enteric Fever in Asia Project (SEAP) conducts prospective enteric fever surveillance in Bangladesh, Nepal, and Pakistan. This supplement presents findings from Phase II of the study (2016–2019) on burden of disease, clinical presentation, the growing spread of drug-resistant strains, and policy and economic ramifications. These findings are delivered to support policymakers in their deliberations on strategies to introduce typhoid conjugate vaccine as a preventive tool against enteric fever.
Typhoid fever, a type of enteric fever transmitted through consumption of food or water contaminated with Salmonella enterica subspecies Typhi, continues to cause illness in Asia. Since the World Health Organization recommended use of typhoid conjugate vaccines in 2018, several countries have introduced or begun the decision-making process to use the vaccine in campaigns or by introduction into the routine immunization schedule. This paper describes the disease burden and vaccine implementation policy setting in the region, based on presentations and discussions at the second Asia Regional Meeting on Typhoid & TCV. Moving forward, typhoid control efforts must prioritize 1) working across health and finance ministries to finance vaccination programs, 2) strengthening surveillance to better understand disease burden, drug resistance trends, and vaccine impact, 3) developing improved diagnostic tests, 4) stewarding antimicrobial use to slow the spread of drug resistance, and 5) evaluating the durability of TCV protection.
Background: Enteric fever, caused by Salmonella Typhi or Paratyphi, is a major public health issue in low- and middle-income countries. Accurate burden estimation is hampered by limited microbiological facilities and low sensitivity of blood-culture tests. Serosurveillance offers a scalable alternative to address these challenges. This study estimated the seroincidence of enteric fever in Bangladesh using cross-sectional rapid serosurveys. Methods: School-based surveys (January–June 2022) were conducted in Chattogram, Dinajpur, Sylhet, Satkhira, and Faridpur, and community-based surveys (July 2019–November 2021) were conducted in Dhaka and Mirzapur. Blood samples (dried blood spots or venous blood) were collected and tested for anti-hemolysin E IgG responses using a kinetic enzyme-linked immunosorbent assay. Seroincidence was estimated using a maximum likelihood approach based on peak antibody titers and decay rates, modeled from blood-culture confirmed enteric fever cases in Bangladesh. Findings: A total of 2969 participants aged 0–22 years were enrolled, with 75.5% aged 5–15 years. Seroincidence rates (per 100 person-years) were highest in Dhaka (33.1; 95% confidence interval [CI], 29.0–37.9), followed by Mirzapur (19.5; 95% CI, 17.4–21.7) and Chattogram (17.1; 95% CI, 15.0–19.4), and the lowest in Faridpur (11.1; 95% CI, 9.6–12.7). The under 5 age group exhibited higher rates in Dhaka (40.3; 95% CI, 32.1–50.7) and Mirzapur (26.1; 95% CI, 21.0–32.4) compared to older age groups. Seroincidence was higher in areas with higher population density. Conclusions: This study highlights a substantial burden of enteric fever infections across Bangladesh. These provide important evidence to guide post-introduction monitoring and optimization of the typhoid conjugate vaccine program in the national immunization schedule.
Twenty years after the introduction of rotavirus vaccines, the 15th International Rotavirus Symposium convened researchers, clinicians, immunization program managers, and policymakers to review advances in rotavirus epidemiology, immunology, vaccine development, and implementation. Rotavirus vaccination has contributed to sustained reductions in severe rotavirus hospitalizations and child mortality, yet population-level benefits remain heterogeneous and are constrained by gaps in coverage, supply-related program disruptions, and context-specific vaccine performance. Presenters highlighted evidence from multi-pathogen surveillance confirming that rotavirus remains a leading cause of pediatric diarrhea requiring hospitalization despite widespread vaccine introduction. Accumulating evidence implicates maternally derived antibodies, environmental enteric dysfunction, and early-life microbiome development as contributors to reduced oral vaccine performance in low- and middle-income communities, while recent studies of next-generation vaccine candidates underscore the need for improved correlates of protection and clinically meaningful efficacy endpoints. Collectively, the symposium emphasized that further reductions in rotavirus morbidity and mortality will require strengthening delivery of existing vaccines—including improving coverage, minimizing supply interruptions, and reaching zero-dose and under-immunized children—while sustaining surveillance and investing in integrated enteric disease prevention and next-generation vaccines to optimize protection in high-burden settings.
Background Global shortages of oral cholera vaccine have led to widespread use of single-dose vaccination. Although this approach increases immediate population coverage, protection may be less durable and effectiveness is lower in young children. Evidence remains limited on whether extending the interval before the second dose of Euvichol-S preserves the immune response achieved with the recommended two-week schedule. Protocol This phase IV, parallel-group, open-label, randomized non-inferiority trial is being conducted in Mukuru, Nairobi, Kenya. A total of 1,071 participants aged ≥1 year are being randomized 1:1:1 to receive a second Euvichol-S dose after two weeks, three months, or twelve months. Randomization is stratified by age group: 1–4 years, 5–14 years, and ≥ 15 years. The respective permitted dose-2 windows are Days 11–17, Days 83–97, and Days 351–379. The primary outcome is the plasma vibriocidal antibody response against Vibrio cholerae O1 Inaba and Ogawa, measured 14 days after the second dose. Each extended schedule will be compared with the two-week schedule within each age group using a geometric mean titre ratio and a non-inferiority margin of 0.90. The primary analysis will use the per-protocol population, with intention-to-treat analyses conducted as sensitivity analyses. Secondary outcomes include seroconversion, persistence of vibriocidal responses, laboratory-confirmed cholera, and safety. A paediatric peripheral blood mononuclear cell sub-cohort is evaluating plasmablast and memory B-cell responses. Discussion The trial will provide evidence on whether longer intervals before the second Euvichol-S dose preserve vaccine-induced immune responses across age groups. Because the primary outcome is immunological, implications for clinical protection and vaccination policy will require cautious interpretation. Trial registration: Pan African Clinical Trials Registry, PACTR202501835187008. Registered 28 January 2025.